Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction

References

• Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246. doi:10.3389/fped.2019.00246
   PubMed Web of Science ®Google Scholar
• Zahran H, Bailey C, Damon S, Garbe P, Breysse P Vital signs: asthma in children — United States, 2001–2016; 2018.
   Google Scholar
• Gibson GJ, Loddenkemper R, Lundbäck B, Sibille Y. Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J. 2013;42(3):559. doi:10.1183/09031936.00105513
   PubMed Web of Science ®Google Scholar
• Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. N Engl J Med. 1995;332(3):133–138. doi:10.1056/NEJM199501193320301
   PubMed Web of Science ®Google Scholar
• Spycher BD, Silverman M, Brooke AM, Minder CE, Kuehni CE. Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. Eur Respir J. 2008;31(5):974. doi:10.1183/09031936.00153507
   PubMed Web of Science ®Google Scholar
• Kuehni CE, Brooke AM, Strippoli M-PF, Wels BD, Davis A, Silverman M. Cohort profile: the Leicester Respiratory Cohorts. Int J Epidemiol. 2007;36(5):977–985. doi:10.1093/ije/dym090
   Web of Science ®Google Scholar
• Henderson J, Granell R, Heron J, et al. Associations of wheezing phenotypes in the first 6 years of life with atopy, lung function and airway responsiveness in mid-childhood. Thorax. 2008;63(11):974–980. doi:10.1136/thx.2007.093187
   PubMed Web of Science ®Google Scholar
• Fainardi V, Santoro A, Caffarelli C. Preschool wheezing: trajectories and long-term treatment. Front Pediatr. 2020;8:240. doi:10.3389/fped.2020.00240
   Web of Science ®Google Scholar
• Brand PLP, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J. 2008;32(4):1096. doi:10.1183/09031936.00002108
   PubMed Web of Science ®Google Scholar
• Garcia-Marcos L, Martinez FD. Multitrigger versus episodic wheeze in toddlers: new phenotypes or severity markers? J Allergy Clin Immunol. 2010;126(3):489–490. doi:10.1016/j.jaci.2010.06.037
   Web of Science ®Google Scholar
• Spycher BD, Cochrane C, Granell R, et al. Temporal stability of multitrigger and episodic viral wheeze in early childhood. Eur Respir J. 2017;50(5):1700014. doi:10.1183/13993003.00014-2017
   Web of Science ®Google Scholar
• Marshall L, Beardsmore CS, Pescatore AM, Kuehni CE, Gaillard EA. Airway eosinophils in older teenagers with outgrown preschool wheeze: a pilot study. Eur Respir J. 2015;46(5):1486. doi:10.1183/13993003.00174-2015
   Web of Science ®Google Scholar
• Welsh KG, Holden KA, Wardlaw AJ, et al. Fungal sensitization and positive fungal culture from sputum in children with asthma are associated with reduced lung function and acute asthma attacks respectively. Clin Exp Allergy. 2020. doi:10.1111/cea.13799
   Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA); 2019. Difficult-to-treat and severe asthma guide. Available from: https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf. Accessed May 7, 2021
   Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Lo DK, Beardsmore CS, Roland D, et al. Lung function and asthma control in school-age children managed in UK primary care: a cohort study. Thorax. 2020;75(2):101. doi:10.1136/thoraxjnl-2019-213068
   PubMed Web of Science ®Google Scholar
• Ahmed H, Turner S. Severe asthma in children—a review of definitions, epidemiology, and treatment options in 2019. Pediatr Pulmonol. 2019;54(6):778–787. doi:10.1002/ppul.24317
   PubMed Web of Science ®Google Scholar
• Guilbert TW, Bacharier LB, Fitzpatrick AM. Severe asthma in children. J Allergy Clin Immunol Pract. 2014;2(5):489–500. doi:10.1016/j.jaip.2014.06.022
   PubMed Web of Science ®Google Scholar
• Fleming L, Murray C, Bansal AT, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J. 2015;46(5):1322. doi:10.1183/13993003.00780-2015
   PubMed Web of Science ®Google Scholar
• Bush A, Saglani S. Management of severe asthma in children. Lancet. 2010;376(9743):814–825. doi:10.1016/S0140-6736(10)61054-9
   PubMed Web of Science ®Google Scholar
• Bush A, Hedlin G, Carlsen K-H, de Benedictis F, Lodrup-Carlsen K, Wilson N. Severe childhood asthma: a common international approach? Lancet. 2008;372(9643):1019–1021. doi:10.1016/S0140-6736(08)61422-1
   PubMed Web of Science ®Google Scholar
• McDonald VM, Yorke J. Adherence in severe asthma: time to get it right. Eur Respir J. 2017;50(6):1702191. doi:10.1183/13993003.02191-2017
   PubMed Web of Science ®Google Scholar
• Mendy A, Wilkerson J, Salo PM, Zeldin DC, Thorne PS. Endotoxin clustering with allergens in house dust and asthma outcomes in a U.S. national study. Environl Health. 2020;19(1):35. doi:10.1186/s12940-020-00585-y
   Web of Science ®Google Scholar
• Puranik S, Forno E, Bush A, Celedón JC. Predicting severe asthma exacerbations in children. Am J Respir Crit Care Med. 2017;195(7):854–859. doi:10.1164/rccm.201606-1213PP
   PubMed Web of Science ®Google Scholar
• Pfeffer PE, Mudway IS, Grigg J. Air pollution and asthma: mechanisms of harm and considerations for clinical interventions. Chest. 2020.
   Web of Science ®Google Scholar
• Osman LM. Psychological factors in asthma control and attack risk. Thorax. 2002;57(3):190. doi:10.1136/thorax.57.3.190
   Web of Science ®Google Scholar
• Barker N, Thevasagayam R, Ugonna K, Kirkby J. Pediatric dysfunctional breathing: proposed components, mechanisms, diagnosis, and management. Front Pediatr. 2020;8:379. doi:10.3389/fped.2020.00379
   Web of Science ®Google Scholar
• De Jong HJI, Voorham J, Scadding GK, et al. Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care. World Allergy Organ J. 2020;13(12):100490. doi:10.1016/j.waojou.2020.100490
   Web of Science ®Google Scholar
• Dixon AE. Rhinosinusitis and asthma: the missing link. Curr Opin Pulm Med. 2009;15(1):19–24. doi:10.1097/MCP.0b013e32831da87e
   PubMed Web of Science ®Google Scholar
• Saragondlu Lakshminarasappa D, Chandrasekaran V, Kandasamy P. Co-morbid anxiety and depression in childhood asthma and its effect on symptom control: a cross sectional study. Pediatr Pulmonol. 2021;56(2):378–383. doi:10.1002/ppul.25180
   PubMed Web of Science ®Google Scholar
• Bantulà M, Roca-Ferrer J, Arismendi E, Picado C. Asthma and obesity: two diseases on the rise and bridged by inflammation. J Clin Med. 2021;10(2):169. doi:10.3390/jcm10020169
   PubMed Web of Science ®Google Scholar
• Smith H, Horney D, Jones C, Goubet S, Mukhopadhyay S, Frew A. Pragmatic randomized controlled trial of an allergy intervention for children aged 6–16 with asthma and rhinitis in general practice. Clin Exp Allergy. 2016;46(9):1227–1235. doi:10.1111/cea.12781
   Web of Science ®Google Scholar
• Gold DR, Adamkiewicz G, Arshad SH, et al. NIAID, NIEHS, NHLBI, and MCAN Workshop Report: the indoor environment and childhood asthma—implications for home environmental intervention in asthma prevention and management. J Allergy Clin Immunol. 2017;140(4):933–949. doi:10.1016/j.jaci.2017.04.024
   PubMed Web of Science ®Google Scholar
• Galeone C, Scelfo C, Bertolini F, et al. Precision medicine in targeted therapies for severe asthma: is there any place for “Omics” technology? Biomed Res Int. 2018;2018:1–15. doi:10.1155/2018/4617565
   Web of Science ®Google Scholar
• European Lung Foundation; 2021. Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED). Available from: https://europeanlung.org/en/projects-and-campaigns/past-projects/u-biopred. Accessed May 7, 2021
   Google Scholar
• Bush A, Bhatt J, Grigg J. E cigarettes: tar wars: the (Tobacco) empire strikes back. Arch Dis Child. 2019;104(11):1027–1039. doi:10.1136/archdischild-2018-315820
   PubMed Web of Science ®Google Scholar
• Turner S, Mackay D, Dick S, Semple S, Pell JP. Associations between a smoke-free homes intervention and childhood admissions to hospital in Scotland: an interrupted time-series analysis of whole-population data. Lancet Public Health. 2020;5(9):e493–e500. doi:10.1016/S2468-2667(20)30178-X
   Web of Science ®Google Scholar
• Fainardi V, Saglani S. An approach to the management of children with problematic severe asthma. Acta Biomed. 2020;91(3):e2020055.
   Google Scholar
• Jochmann A, Artusio L, Jamalzadeh A, et al. Electronic monitoring of adherence to inhaled corticosteroids: an essential tool in identifying severe asthma in children. Eur Respir J. 2017;50(6):1700910. doi:10.1183/13993003.00910-2017
   PubMed Web of Science ®Google Scholar
• WHO; 2003. Adherence to long-term therapies. Available from: https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed May 7, 2021.
   Google Scholar
• van Boven JFM, Trappenburg JCA, van der Molen T, Chavannes NH. Towards tailored and targeted adherence assessment to optimise asthma management. NPJ Prim Care Respir Med. 2015;25:15046. doi:10.1038/npjpcrm.2015.46
   PubMed Web of Science ®Google Scholar
• Sleath B, Ayala GX, Gillette C, et al. Provider demonstration and assessment of child device technique during pediatric asthma visits. Pediatrics. 2011;127(4):642–648. doi:10.1542/peds.2010-1206
   PubMed Web of Science ®Google Scholar
• Sanchis J, Gich I, Pedersen S. Systematic review of errors in inhaler use: has patient technique improved over time? CHEST. 2016;150(2):394–406. doi:10.1016/j.chest.2016.03.041
   PubMed Web of Science ®Google Scholar
• Gillette C, Rockich-Winston N, Kuhn JA, Flesher S, Shepherd M. Inhaler technique in children with asthma: a systematic review. Acad Pediatr. 2016;16(7):605–615. doi:10.1016/j.acap.2016.04.006
   PubMed Web of Science ®Google Scholar
• Kocks JWH, Chrystyn H, van der Palen J, et al. Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD. NPJ Prim Care Respir Med. 2018;28(1):43. doi:10.1038/s41533-018-0110-x
   PubMed Web of Science ®Google Scholar
• Shields MD, ALQahtani F, Rivey MP, McElnay JC. Mobile direct observation of therapy (MDOT) - A rapid systematic review and pilot study in children with asthma. PLoS One. 2018;13(2):e0190031. doi:10.1371/journal.pone.0190031
   PubMed Web of Science ®Google Scholar
• Harrington CB, Langhans E, Shelef DQ, Savitz M, Whitmore C, Teach SJ. A pilot randomized trial of school-based administration of inhaled corticosteroids for at-risk children with asthma. J Asthma. 2018;55(2):145–151.
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Diamant Z, Bakakos P, Loukides S. Towards precision medicine in severe asthma: treatment algorithms based on treatable traits. Respir Med. 2018;142:15–22. doi:10.1016/j.rmed.2018.07.006
   PubMed Web of Science ®Google Scholar
• Vijverberg SJH, Brinkman P, Rutjes NWP, Maitland-van der Zee AH. Precision medicine in severe pediatric asthma: opportunities and challenges. Curr Opin Pulm Med. 2020;26(1):77–83. doi:10.1097/MCP.0000000000000633
   Web of Science ®Google Scholar
• Wenzel SE. Severe adult asthmas: integrating clinical features, biology and therapeutics to improve outcomes. Am J Respir Crit Care Med. 2020.
   Google Scholar
• Nelson RK, Bush A, Stokes J, Nair P, Akuthota P. Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2020;8(2):465–473. doi:10.1016/j.jaip.2019.11.024
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Chipps BE, Holguin F, Woodruff PG. T2-“Low” asthma: overview and management strategies. J Allergy Clin Immunol Pract. 2020;8(2):452–463. doi:10.1016/j.jaip.2019.11.006
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Colice G, Griffiths JM, et al. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020;21(1):266. doi:10.1186/s12931-020-01526-6
   PubMed Web of Science ®Google Scholar
• Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018;73(12):1110. doi:10.1136/thoraxjnl-2018-211540
   PubMed Web of Science ®Google Scholar
• Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615. doi:10.1164/rccm.9120-11ST
   PubMed Web of Science ®Google Scholar
• Fleming L, Tsartsali L, Wilson N, Regamey N, Bush A. Longitudinal relationship between sputum eosinophils and exhaled nitric oxide in children with asthma. Am J Respir Crit Care Med. 2013;188(3):400–402. doi:10.1164/rccm.201212-2156LE
   PubMed Web of Science ®Google Scholar
• Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol. 2013;132(4):821–827.e5. doi:10.1016/j.jaci.2013.06.007
   PubMed Web of Science ®Google Scholar
• Heaney LG, Busby J, Bradding P, et al. Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma. Am J Respir Crit Care Med. 2018;199(4):454–464. doi:10.1164/rccm.201806-1182OC
   Web of Science ®Google Scholar
• Grol MH, Postma DS, Vonk JM, et al. Risk factors from childhood to adulthood for bronchial responsiveness at age 32–42 yr. Am J Respir Crit Care Med. 1999;160(1):150–156. doi:10.1164/ajrccm.160.1.9707103
   Web of Science ®Google Scholar
• CONTROLLED trial of effects of cortisone acetate in status asthmaticus; report to the Medical Research Council by the subcommittee on clinical trials in asthma. Lancet. 1956;271:803–806.doi:10.1016/S0140-6736(56)92241-3
   Google Scholar
• Morrow Brown H. Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet. 1958;272(7059):1245–1247. doi:10.1016/S0140-6736(58)91385-0
   Google Scholar
• Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J. 1972;1(5800):585–590. doi:10.1136/bmj.1.5800.585
   PubMed Web of Science ®Google Scholar
• Brown HM, Storey G, Jackson FA. Beclomethasone dipropionate aerosol in long-term treatment of perennial and seasonal asthma in children and adults: a report of five-and-half years’ experience in 600 asthmatic patients. Br J Clin Pharmacol. 1977;4 Suppl 3(Suppl3):259S–267S. doi:10.1111/j.1365-2125.1977.tb04517.x
   Web of Science ®Google Scholar
• Welsh KG, Rousseau K, Fisher G, et al. MUC5AC and a glycosylated variant of MUC5B alter mucin composition in children with acute asthma. Chest. 2017;152(4):771–779. doi:10.1016/j.chest.2017.07.001
   PubMed Web of Science ®Google Scholar
• Saglani S, Lloyd CM. Eosinophils in the pathogenesis of paediatric severe asthma. Curr Opin Allergy Clin Immunol. 2014;14(2). doi:10.1097/ACI.0000000000000045
   Web of Science ®Google Scholar
• O’Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol. 2001;108(4):503–508. doi:10.1067/mai.2001.119149
   PubMed Web of Science ®Google Scholar
• Sur S, Gleich GJ, Swansonb MC, Bartemesb KR, Broide DH. Eosinophilic inflammation is associated with elevation of interleukin-5 in the airways of patients with spontaneous symptomatic asthma.J. Allergy Clin Immunol. 1995;96(5):661–668. doi:10.1016/S0091-6749(95)70265-2
   Google Scholar
• Gaillard EA, McNamara PS, Murray CS, Pavord ID, Shields MD. Blood eosinophils as a marker of likely corticosteroid response in children with preschool wheeze: time for an eosinophil guided clinical trial? Clin Exp Allergy. 2015;45(9):1384–1395. doi:10.1111/cea.12535
   PubMed Web of Science ®Google Scholar
• Holden KA, Roland D, Welsh KG, Gaillard EA. Comparison of blood eosinophil numbers between acute asthma and stable disease in children with preschool wheeze. Pediatr Allergy Immunol Pulmonol. 2017;30(4):210–217. doi:10.1089/ped.2017.0802
   Web of Science ®Google Scholar
• Nadif R, Siroux V, Oryszczyn M-P, et al. Heterogeneity of asthma according to blood inflammatory patterns. Thorax. 2009;64(5):374. doi:10.1136/thx.2008.103069
   PubMed Web of Science ®Google Scholar
• Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur Respir J. 2018;51(4):1702536. doi:10.1183/13993003.02536-2017
   PubMed Web of Science ®Google Scholar
• Taylor KJ, Luksza AR. Peripheral blood eosinophil counts and bronchial responsiveness. Thorax. 1987;42(6):452–456. doi:10.1136/thx.42.6.452
   PubMed Web of Science ®Google Scholar
• Koh Y, Choi S. Blood eosinophil counts for the prediction of the severity of exercise-induced bronchospasm in asthma. Respir Med. 2002;96(2):120–125. doi:10.1053/rmed.2001.1238
   PubMed Web of Science ®Google Scholar
• Little SA, Chalmers GW, MacLeod KJ, McSharry C, Thomson NC. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax. 2000;55(3):232–234. doi:10.1136/thorax.55.3.232
   Web of Science ®Google Scholar
• Chlumský J, Striz I, Terl M, Vondracek J. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res. 2006;34(2):129–139. doi:10.1177/147323000603400202
   PubMed Web of Science ®Google Scholar
• Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27(3):483. doi:10.1183/09031936.06.00137704
   PubMed Web of Science ®Google Scholar
• Norzila MZ, Fakes K, Henry RL, Simpson J, Gibson PG. Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma. Am J Respir Crit Care Med. 2000;161(3):769–774. doi:10.1164/ajrccm.161.3.9809071
   PubMed Web of Science ®Google Scholar
• Fleming L, Tsartsali L, Wilson N, Regamey N, Bush A. Sputum inflammatory phenotypes are not stable in children with asthma. Thorax. 2012;67(8):675. doi:10.1136/thoraxjnl-2011-201064
   PubMed Web of Science ®Google Scholar
• Tan L, Chupp G, Castro M, Kraft M. Going beyond “Bio-markers,” Think “Life-markers”. Chest. 2020;157(3):503–505. doi:10.1016/j.chest.2019.08.2210
   PubMed Web of Science ®Google Scholar
• Matucci A, Vultaggio A, Maggi E, Kasujee I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respir Res. 2018;19(1):113. doi:10.1186/s12931-018-0813-0
   PubMed Web of Science ®Google Scholar
• Punnonen J, Yssel H, de Vries JE. The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells. J Allergy Clin Immunol. 1997;100(6 Pt 1):792–801. doi:10.1016/S0091-6749(97)70276-8
   Web of Science ®Google Scholar
• Kraft S, Kinet JP. New developments in FcεRI regulation, function and inhibition. Nat Rev Immunol. 2007;7:365–378. doi:10.1038/nri2072
   PubMed Web of Science ®Google Scholar
• Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A, Pelaia G. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Ther Adv Respir Dis. 2018;12:175346661881019. doi:10.1177/1753466618810192
   Web of Science ®Google Scholar
• Bousquet J, Wahn U, Meltzer EO, et al. Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases. Eur Respir Rev. 2008;17(107):1. doi:10.1183/09059180.00010701
   Google Scholar
• Normansell R, Walker S, Milan S, Walters E, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1.
   Google Scholar
• Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.J. Allergy Clin Immunol. 2009;124(6):1210–1216. doi:10.1016/j.jaci.2009.09.021
   Google Scholar
• Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (Omalizumab). Pediatrics. 2001;108(2):e36. doi:10.1542/peds.108.2.e36
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–1015. doi:10.1056/NEJMoa1009705
   PubMed Web of Science ®Google Scholar
• Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. The Journal of Allergy and Clinical Immunology: In Practice. 2021. doi:10.1016/j.jaip.2021.01.011
   Web of Science ®Google Scholar
• Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162–169.e2. doi:10.1016/j.jaci.2016.08.054
   PubMed Web of Science ®Google Scholar
• Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42(5):1224. doi:10.1183/09031936.00149812
   PubMed Web of Science ®Google Scholar
• Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol. 2003;91(2):182–188. doi:10.1016/S1081-1206(10)62175-8
   Web of Science ®Google Scholar
• Leckie MJ, Brinke AT, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144–2148. doi:10.1016/S0140-6736(00)03496-6
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071. doi:10.1164/rccm.200701-085OC
   PubMed Web of Science ®Google Scholar
• Pavord ID, Menzies-Gow A, Buhl R, et al. Clinical development of mepolizumab for the treatment of severe eosinophilic asthma: on the path to personalized medicine. J Allergy Clin Immunol;2020. S2213219820308710. doi:10.1016/j.jaci.2019.12.006
   Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984. doi:10.1056/NEJMoa0808991
   PubMed Web of Science ®Google Scholar
• Nair P, Kjarsgaard M, Efthimiadis A, Hargreave FE. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009. doi:10.1056/NEJMoa0805435
   Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X
   PubMed Web of Science ®Google Scholar
• Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017.
   Web of Science ®Google Scholar
• EMA; 2018. Assessment report Nucala. Available from: https://www.ema.europa.eu/en/documents/variation-report/nucala-h-c-3860-ii-0013-g-epar-assessment-report-variation_en.pdf. Accessed May 7, 2021.
   Google Scholar
• Gupta A, Ikeda M, Geng B, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019;144(5):1336–1342.e7. doi:10.1016/j.jaci.2019.08.005
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a Randomized Phase 3 Study. CHEST. 2016;150(4):789–798. doi:10.1016/j.chest.2016.03.032
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi:10.1016/S2213-2600(15)00042-9
   PubMed Web of Science ®Google Scholar
• Pijnenburg MW, Fleming L. Advances in understanding and reducing the burden of severe asthma in children. Lancet Respir Med. 2020;8(10):S2213260020303994. doi:10.1016/S2213-2600(20)30399-4
   Web of Science ®Google Scholar
• Menzella F, Lusuardi M, Galeone C, Facciolongo N, Zucchi L. The clinical profile of benralizumab in the management of severe eosinophilic asthma. Ther Adv Respir Dis. 2016;10(6):534–548. doi:10.1177/1753465816667659
   PubMed Web of Science ®Google Scholar
• Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33(1):14–20. doi:10.1016/j.ajem.2014.09.036
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–890. doi:10.1016/S2213-2600(14)70201-2
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. PK/PD and long term safety study of benralizumab in children with severe eosinophilic asthma (TATE). Available from: https://clinicaltrials.gov/ct2/show/NCT04305405. Accessed May 7, 2021.
   Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466. doi:10.1056/NEJMoa1304048
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Vatrella A, Tinello C, Terracciano R, Pelaia G. Molecular targets for biological therapies of severe asthma. Front Immunol. 2020;11:603312. doi:10.3389/fimmu.2020.603312
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa1804093
   PubMed Web of Science ®Google Scholar
• Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1058–1068. doi:10.1111/all.14268
   PubMed Web of Science ®Google Scholar
• Castro M, Rabe KF, Corren J, et al. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. ERJ Open Res. 2020;6(1):00204–02019. doi:10.1183/23120541.00204-2019
   PubMedGoogle Scholar
• Busse WW, Maspero JF, Rabe KF, et al. Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther. 2018;35:737–748. doi:10.1007/s12325-018-0702-4
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. VOYAGE. Available from: https://clinicaltrials.gov/ct2/show/NCT02948959. Accessed May 7, 2021.
   Google Scholar
• Marone G, Spadaro G, Braile M, et al. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. Expert Opin Investig Drugs. 2019;28(11):931–940.
   PubMedGoogle Scholar
• Mitchell PD, O’Byrne PM. Epithelial-derived cytokines in asthma. Chest. 2017;151(6):1338–1344. doi:10.1016/j.chest.2016.10.042
   PubMed Web of Science ®Google Scholar
• Corren J, Ziegler SF. TSLP: from allergy to cancer. Nat Immunol. 2019;20(12):1603–1609. doi:10.1038/s41590-019-0524-9
   PubMed Web of Science ®Google Scholar
• Ziegler SF, Roan F, Bell BD, Stoklasek TA, Kitajima M, Han H. The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol. 2013;66:129–155.
   PubMedGoogle Scholar
• Bunyavanich S, Melen E, Wilk JB, et al. Thymic stromal lymphopoietin (TSLP) is associated with allergic rhinitis in children with asthma. Clin Mol Allergy. 2011;9:1. doi:10.1186/1476-7961-9-1
   PubMedGoogle Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–946. doi:10.1056/NEJMoa1704064
   PubMed Web of Science ®Google Scholar
• AstraZeneca; 2020. Tezepelumab NAVIGATOR Phase III trial met primary endpoint of a statistically significant and clinically meaningful reduction in exacerbations in a broad population of patients with severe asthma . Available from: https://www.astrazeneca.com/media-centre/press-releases/2020/tezepelumab-navigator-phase-iii-trial-met-primary-endpoint.html. Accessed May 7, 2021.
   Google Scholar
• AstraZeneca; 2020. Update on SOURCE Phase III trial for tezepelumab in patients with severe, oral corticosteroid-dependent asthma. Available from: https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-source-phase-iii-trial-for-tezepelumab-in-patients-with-severe-oral-corticosteroid-dependent-asthma.html. Accessed May 7, 2021.
   Google Scholar
• Bush A. Azithromycin is the answer in paediatric respiratory medicine, but what was the question? PRR. 2020;34:67–74.
   Google Scholar
• Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–668. doi:10.1016/S0140-6736(17)31281-3
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019
   PubMed Web of Science ®Google Scholar
• Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2016;4(9):699–707. doi:10.1016/S2213-2600(16)30179-5
   PubMed Web of Science ®Google Scholar
• Brightling CE, Gaga M, Inoue H, et al. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir Med. 2021;9(1):43–56. doi:10.1016/S2213-2600(20)30412-4
   PubMedGoogle Scholar
• Christensen MA, Ott M. Innovative Therapies for Severe Asthma. Fed Pract. 2017;34(12):25–31.
   Google Scholar
• Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med. 2007;356(13):1327–1337. doi:10.1056/NEJMoa064707
   PubMed Web of Science ®Google Scholar
• Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181(2):116–124. doi:10.1164/rccm.200903-0354OC
   PubMed Web of Science ®Google Scholar
• Chaudhuri R, Rubin A, Sumino K, et al. Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respir Med. 2021;9(5):457–466. doi:10.1016/S2213-2600(20)30408-2
   PubMed Web of Science ®Google Scholar